Follow
Nada Agbariah
Nada Agbariah
Universitätsspital Zürich
Verified email at usz.ch
Title
Cited by
Cited by
Year
Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients
S Facchin, A Buda, R Cardin, N Agbariah, F Zingone, M De Bona, ...
Therapeutic Advances in Gastroenterology 14, 1756284821999902, 2021
192021
Immune-mediated thrombotic thrombocytopenic purpura following mRNA-based COVID-19 vaccine BNT162b2: case report and mini-review of the literature
VA Buetler, N Agbariah, DP Schild, FD Liechti, A Wieland, N Andina, ...
Frontiers in medicine 9, 890661, 2022
62022
Acquired immune-mediated thrombotic thrombocytopenic pur-pura (iTTP) following mRNA-based COVID-19 vaccination (BNT162b2)
N Agbariah, VA Bütler, A Wieland, N Andina, F Hammann, ...
Swiss Medical Weekly, 20S-20S, 2021
32021
“A Dangerous Black Box:” Idiopathic Hemophagocytic Lymphohistiocytosis in Adult Patients—A Case Report and Review of the Literature
N Agbariah, J Sanz, A Rovó
Case reports in hematology 2022 (1), 5867129, 2022
22022
P475 rapid point-of-care anti-drug antibodies measurement correlates with standardised T tests and facilitate a proactive therapeutic drug monitoring approach in IBD patients …
S Facchin, A Buda, R Cardin, R D'Incà, F Zingone, N Agbariah, ...
Journal of Crohn's and Colitis 13 (Supplement_1), S349-S350, 2019
22019
Breaking Stereotypes: Polycythemia Secondary to Shisha Smoking in a Middle-Age Swiss Woman
N Agbariah, A Rovó
Acta haematologica 145 (6), 650-654, 2022
2022
P. 07.28 PREVIOUS EXPOSURE TO INFLIXIMAB INDUCES CROSS-REACTIVITY AND AFFECTS ADALIMUMAB TROUGH LEVELS: DATA FROM A PROSPECTIVE, MULTICENTRE STUDY
S Facchin, N Agbariah, A Buda, R Cardin, F Zingone, R D'Incà, ...
Digestive and Liver Disease 51, e234, 2019
2019
The system can't perform the operation now. Try again later.
Articles 1–7